Mostrar el registro sencillo del ítem

dc.contributor.author
Baena, Armando  
dc.contributor.author
Paolino, Melisa Delia  
dc.contributor.author
Villarreal Garza, Cynthia  
dc.contributor.author
Torres, Gabriela  
dc.contributor.author
Delgado, Lucia  
dc.contributor.author
Ruiz, Rossana  
dc.contributor.author
Canelo Aybar, Carlos  
dc.contributor.author
Song, Yang  
dc.contributor.author
Feliu, Ariadna  
dc.contributor.author
Maza, Mauricio  
dc.contributor.author
Jeronimo, Jose  
dc.contributor.author
Espina, Carolina  
dc.contributor.author
Almonte, Maribel  
dc.date.available
2024-06-10T10:31:51Z  
dc.date.issued
2023-10  
dc.identifier.citation
Baena, Armando; Paolino, Melisa Delia; Villarreal Garza, Cynthia; Torres, Gabriela; Delgado, Lucia; et al.; Latin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening; Elsevier; Cancer Epidemiology; 86; 10-2023; 1-13  
dc.identifier.issn
1877-7821  
dc.identifier.uri
http://hdl.handle.net/11336/237560  
dc.description.abstract
Prostate, breast, colorectal, cervical, and lung cancers are the leading cause of cancer in Latin America and the Caribbean (LAC) accounting for nearly 50% of cancer cases and cancer deaths in the region. Following the IARC Code Against Cancer methodology, a group of Latin American experts evaluated the evidence on several medical interventions to reduce cancer incidence and mortality considering the cancer burden in the region. A recommendation to limit the use of HRT was issued based on the risk associated to develop breast, endometrial, and ovarian cancer and on growing concerns related to the over-the-counter and without prescription sales, which in turn bias estimations on current use in LAC. In alignment with WHO breast and cervical cancer initiatives, biennial screening by clinical breast examination (performed by trained health professionals) from the age of 40 years and biennial screening by mammography from the age of 50 years to 74, as well as cervical screening by HPV testing (either self-sampling or provider-sampling) every 5–10 years for women aged 30–64 years, were recommended. The steadily increasing rates of colorectal cancer in LAC also led to recommend colorectal screening by occult blood testing every two years or by endoscopic examination of the colorectum every 10 years for both men and women aged 50–74 years. After evaluating the evidence, the experts decided not to issue recommendations for prostate and lung cancer screening; while there was insufficient evidence on prostate cancer mortality reduction by prostate-specific antigen (PSA) testing, there was evidence of mortality reduction by low-dose computed tomography (LDCT) targeting high-risk individuals (mainly heavy and/or long-term smokers) but not individuals with average risk to whom recommendations of this Code are directed. Finally, the group of experts adapted the gathered evidence to develop a competency-based online microlearning program for building cancer prevention capacity of primary care health professionals.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
Cancer prevention  
dc.subject
Hormone replacement therapy use  
dc.subject
Cancer screening and early diagnosis  
dc.subject
Latin America and the Caribbean Code Against Cance  
dc.subject.classification
Epidemiología  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Latin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-06-07T15:21:24Z  
dc.journal.volume
86  
dc.journal.pagination
1-13  
dc.journal.pais
Países Bajos  
dc.journal.ciudad
Amsterdam  
dc.description.fil
Fil: Baena, Armando. Agencia Internacional de Investigación En Cáncer; Francia  
dc.description.fil
Fil: Paolino, Melisa Delia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios de Estado y Sociedad; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Villarreal Garza, Cynthia. Hospital Zambrano Hellion; México  
dc.description.fil
Fil: Torres, Gabriela. Instituto Nacional de Salud Pública; México  
dc.description.fil
Fil: Delgado, Lucia. Universidad de la República; Uruguay  
dc.description.fil
Fil: Ruiz, Rossana. Instituto Nacional de Enfermedades Neoplasicas; Perú  
dc.description.fil
Fil: Canelo Aybar, Carlos. Biomedical Research Institute Sant Pau; España  
dc.description.fil
Fil: Song, Yang. Biomedical Research Institute Sant Pau; España  
dc.description.fil
Fil: Feliu, Ariadna. International Agency for Research on Cancer; Francia  
dc.description.fil
Fil: Maza, Mauricio. Pan American Health Organization; Estados Unidos  
dc.description.fil
Fil: Jeronimo, Jose. National Institutes of Health; Estados Unidos  
dc.description.fil
Fil: Espina, Carolina. International Agency for Research on Cancer; Francia  
dc.description.fil
Fil: Almonte, Maribel. International Agency for Research on Cancer; Francia  
dc.journal.title
Cancer Epidemiology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.canep.2023.102446